A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 7, 1997, Pages 798-805

  Mckeever, Paul E ^a   Ross, Donald A ^a   Strawderman, Myla S ^b   Brunberg, James A ^b   Greenberg, Harry S ^a   Junck, Larry ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Astrocytoma; BUDR; Glioma; Karnofsky; Ki 67; MIB 1; PCNA

Indexed keywords

BROXURIDINE; CYCLINE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW;

EID: 0030949269     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199756070-00006     Document Type: Review

References (51)

1. Sternberg SS, Antonioli DA, Carter D, Mills SE, Oberman HA. Diagnostic surgical pathology. 2nd ed. New York: Raven Press, 1993
2. Wolfgang B, Dolbeare Gray JW. An improved immunochemical procedure for high-sensitivity detection of incorporated bromodeoxyuridine. Cytometry 1987;8:235-39
3. Onda K, Davis RL, Wilson CB, Hoshino T. Regional differences in bromodeoxyuridine uptake, expression of KI-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol (Berl) 1994;87:586-93
4. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 1994;74:1921-26
5. Gerdes J, Schwab U, Lemke H, Stain H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20
6. Schroder R, Bien K, Kott R, Meyers I, Vossing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: Demonstration of the variability of the intermitotic cycle time. Acta Neuropathol (Berl) 1991;82:389-94
7. McKeever PE, Burger PC, Nelson JS. Introduction to neuro-oncology. In: Nelson JS, Parisi JE, Schochet SS Jr, eds. Principles and practice of neuropathology. St. Louis: Mosby Year Book, 1993:109-22
8. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application of surgical neuropathology. Am J Surg Pathol 1986;10:611-17
9. Parkins CS, Darling JL, Gill SS, Revesz T, Thomas DG. Cell proliferation in serial biopsies through human malignant brain tumors: Measurement using Ki-67 antibody labeling. Br J Neurosurg 1991;5:289-98
10. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63
11. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of Ki-67 antigen in fixed and wax-embedded section with the monoclonal antibody MIB-1. Histopathology 1993;22:355-60
12. Prelich G, Tan C-K, Kostura M, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-S auxiliary protein. Nature 1987;326:517-19
13. Galand P, Degraef C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 1989;22:383-92
14. Jackson DA, Hassan AB, Errington RJ. Cook PR. Sites in human nuclei where damage induced by ultraviolet light is repaired: Localization relative to transcription sites and concentrations of proliferating cell nuclear antigen and the tumour suppressor protein, p53. J Cell Sci 1994;107:1753-60
15. Aboussekhra A, Wood RD. Detection of nucleotide excision repair incisions in human fibroblasts by immunostaining for PCNA. Exp Cell Res 1995;221:326-32
16. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989;134:733-39
17. Revesz T, Alsanjari N, Darling JL, Scaravilli F, Lane DP, Thomas DG. Proliferating cell nuclear antigen (PCNA): Expression in samples of human astrocytic gliomas. Neuropathol Appl Neurobiol 1993;19:152-58
18. Beppu T, Arai H, Kanaya H, Sasaki K. Measurement of PCNA labeling index in astrocytic tumors. No Shinkei Geka 1992;20:1255-59
19. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. 2nd ed. Berlin: Springer-Verlag, 1993
20. Goldblum JR, Shannon R, Kaljian EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-68
21. McKeever PE, Junck L, Ross DA, et al. Comparison of MIB-1, BUDR and PCNA labeling index markers of cellular proliferation in grading astrocytic gliomas [abstract]. Brain Pathology 1994;4:412
22. Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology. 3rd ed. New York: Blakiston Division, McGraw-Hill, 1968
23. Mukhopadhyay SK, McKeever PE, Greenberg HS, Junck L, Chandler WF, Ensminger W. Random sampling by glitter drop method. Life Sci 1990;46:507-12
24. Sallinen P, Haapasalo H, Kerttula T, et al. Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. Anal Quant Cytol Histol 1994;16:261-68
25. Hopf NJ, Bremm J, Bohl J, Perneczky A. Image analysis of proliferating cells in tumors of the human nervous system: An immunohistochemical study with the monoclonal antibody Ki-67. Neurosurgery 1994;35:917-23
26. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-82
27. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995;76:1809-13
28. Korkolopoulou P, Christodoulou P, Lekka-Katsouli I, et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology 1994;25:349-55
29. Theunissen PH, Blaauw G. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology, 1993;23:75-79
30. Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D. Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 1994;21:306-10
31. Khoshyomn S, Maier H, Morimura T, Kitz K, Budka H. Immunostaining for proliferating cell nuclear antigen: Its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol (Berl) 1993;86:582-89
32. Hoyt JW, Gown AM, Kim DK, Berger MS. Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 1995;24:163-69
33. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol (Berlin) 1994;87:47-54
34. Prayson RA, Khajavi K, Comair YG. Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: A study of 60 patients with intracranial tumors. J Neuropathol Exp Neurol 1995;54:513-20
35. Patsouris E, Stocker U, Kallmeyer V, Keiditsch E, Mehraein P, Stavrou D. Relationship between Ki-67 positive cells, growth rate, and histologic type of human intracranial tumors. Anticancer Res 1988;8:537-44
36. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989;115:179-88
37. Tsanaclis AM, Robert F, Michaud J, Brem S. The cycling pool of cells within brain tumors: In situ cytokinetics using the monoclonal antibody Ki-67. Can J Neurol Sci 1991;18:12-17
38. Raghavan R, Steart P, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas, and glioblastoma multiforme: A Ki-67 study. Neuropathol Appl Neurobiol 1990;16:123-33
39. Shibata T, Burger PC, Kleihues P. Ki-67 immunoperoxidase stain as marker for the histologic grading of nervous system tumors. Acta Neurosurg (Suppl) 1988;43:103-6
40. Zuber P, Hamou M-F, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988;22:364-68
41. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66:373-85
42. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-18
43. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery, 1994;34:674-78
44. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathol (Berl) 1991;81:675-79
45. Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988;62:989-93
46. Morimura T, Kitz K, Budka H. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67. Acta Neuropathol (Berl) 1989;77:276-82
47. Shibuya M, Ito S, Miwa T, Davis RL, Wilson CB, Hoshino T. Proliferative potential of brain tumors. Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Cancer 1993;71:199-206
48. McKeever PE, Yamini B, Mikhail AA, et al. Immunocytochemical assessment of proliferative capacity [abstract]. Tenth International Congress of Histochemistry and Cytochemistry, Kyoto, Japan, August 19, 1996
49. Sasaki A, Naganuma H, Kimura R, et al. Proliferating cell? nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumors in paraffin embedded sections. Acta Neurochir 1992;117:178-81
50. Coltrera MD, Gown AM. PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J Histochem Cytochem 1991;39:23-30
51. Carroll PR, Waldman FM, Rosenau W, et al. Cell proliferation in prostatic adenocarcinoma: In vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol 1993;149:403-7